Skip to main content

Table 2 Studies of PCOS and endometrial cancer risk

From: Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review

Author Year Study design Endometrial Cancer Cases (n) Overall result RR (95% CI)
Gottschau 2015 Registry cohort (Denmark) 16 3.9 (2.2–6.3)a
Shen 2015 Registry cohort (Taiwan) 7 4.7 (1.6–14.1)a
Barryb 2014 Meta-analysis 1264 2.8 (1.3–6.0)a
Haoulac 2012 Meta-analysis 938 2.9 (1.5–5.5)a
Brintond 2010 Cohort (US) 15 2.0 (1.1–3.3)a
Fearnleye 2010 Case control (Australia) 156 2.2 (0.9–5.7)
Chittendenf 2009 Meta-analysis 667 2.7 (1.0–7.3)c
Zucchetto 2009 Case–control (Italy) 454 1.3 (0.7–2.2)
Iatrakise 2006 Case–control (Greece) 81 9.0 (0.5–176.0)a,g
Pillayh 2006 Cross-sectional (UK) 128 1.0 (0.4–2.7)a,c
Niwa 2000 Case–control (Japan) 136 8.9 (0.4–184.9)a,g
Wild 2000 Cohort (UK) 11 6.1 (1.0–36.9)
Escobedo 1991 Case–control (US) 437 5.4 (2.4–12.3)a
Coulami 1983 Cohort (US) 5 3.1 (1.1–7.3)a
  1. a Effect estimate not adjusted for BMI
  2. b This meta-analysis includes the studies by Fearnley, Zucchetto, Iatrakis, Niwa, and Escobedo
  3. c This meta-analysis includes the studies by Fearnley, Iatrakis, Pillay, Niwa, and Escobedo
  4. d In this study, androgen excess or menstrual disorders was evaluated rather than PCOS
  5. e This study only included women less than 50 years old
  6. f This meta-analysis includes the studies by Iatrakis, Pillay, Niwa, and Escobedo
  7. g Odds ratio was calculated based on numbers provided in the paper
  8. h In this study, polycystic ovary morphology was evaluated rather than PCOS
  9. i In this study, chronic anovulation syndrome was evaluated rather than PCOS